Market Overview:
The cancer chemotherapy associated nausea and vomiting therapeutics market consists of drugs used for the prevention and treatment of nausea and vomiting as side effects of chemotherapy in cancer patients. The therapeutics act by blocking specific neurotransmitter receptors in the brain to reduce nausea and vomiting.
The Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the cancer chemotherapy associated nausea and vomiting therapeutics market is the adoption of novel drug formulations and delivery systems. Companies are focusing on the development of drugs with increased bioavailability and longer duration of action to improve patient compliance. For instance, sustained release formulations prevent frequent dosing and maintain optimal drug levels for a prolonged period. This helps reduce nausea and vomiting more effectively. New drugs are also being developed which act through different mechanisms and on novel receptors & pathways to broaden treatment options for patients.
SWOT Analysis
Strength: The cancer chemotherapy associated nausea and vomiting therapeutics market is witnessing significant research and development activities for development of novel and effective drugs and devices. This is expected to drive the market growth.
Weakness: High costs associated with drug development and clinical trials for cancer chemotherapy associated nausea and vomiting therapeutics poses a major challenge.
Opportunity: Rising prevalence of cancer worldwide presents lucrative opportunities for players in this market. Additionally, increasing adoption of combination therapies for chemotherapy-induced nausea and vomiting presents new opportunities.
Threats: Stringent regulatory framework and delays in approval process can hamper the growth of this market. Additionally, presence of alternative treatment methods poses threat to chemotherapy associated nausea and vomiting therapeutics.
Key Takeaways
The Global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of cancer worldwide. The market size for 2023 is estimated to be US$ 3,071.1 Mn.
Regional analysis: North America is expected to dominate the global market over the forecast period owing to high healthcare spending and growing cancer rates in the region. However, Asia Pacific is anticipated to exhibit fastest growth due to rising awareness, improving healthcare infrastructure, and increasing adoption of advanced technologies in emerging economies like India and China.
Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics are Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd. These companies focus on innovating novel therapeutics to cater to the rising treatment demands.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
